Background

The Joint Drug Program is structurally the union's victory: it is jointly adopted, jointly administered through an Independent Program Administrator with no affiliation to either party, and disputes are resolved through the Grievance Procedure of the Basic Agreement (not unilaterally by the Commissioner). This stands in sharp contrast to the pre-2002 era, when drug discipline was largely a unilateral commissioner-office matter (see the 1991 Vincent Memo and 1997 Selig Memo, both in the WANTLIST). The Program is the post-Mitchell-Report evolution of MLB drug policy — formalized via the 2002 CBA and progressively strengthened through subsequent CBA cycles. Current PED discipline: 80 games first offense, 162 games second offense, permanent ban (with possibility of MLB reinstatement after two years) for third offense. Stimulant penalties are escalating but milder. Section 5.E ('Public Statements Undermining Integrity of the Program') is the provision that has been invoked when players publicly criticize the program — itself a notable speech restriction in the labor context. Cite specific Section numbers when analyzing suspensions; flag that the Independent Program Administrator structure is a structural protection against unilateral commissioner discipline that did not exist pre-2002.

Key provisions

• Purposes (preamble): (i) educate Players on the risks of Prohibited Substances; (ii) deter and end use of Prohibited Substances; (iii) provide orderly resolution of disputes — with disputes resolved through the Basic Agreement's Grievance Procedure except where otherwise provided.
• Coverage (preamble): all Players on 40-man rosters; any Player on the Restricted List or 60-day Injured List; any Player who becomes a free agent under Article XIX or Article XX of the Basic Agreement; any Player released from a Major League roster (unless voluntarily retired or signing a Minor League contract with an unaffiliated professional baseball club); Foreign Professionals and Certain Free Agents per Attachments 3 and 4.
• Section 1 — Oversight and Administration (pp. 1–8): Independent Program Administrator (IPA, jointly selected, no affiliation with either party); Treatment Board; Collection Services; Laboratory Analysis; Medical Testing Officer; Expert Panel on ADHD; Medical Advisory Panel; Annual Review of the Program.
• Section 2 — Prohibited Substances (pp. 8–15): Drugs of Abuse; Performance Enhancing Substances; Stimulants; DHEA; Diuretics and Masking Agents; mechanism for Adding Prohibited Substances to the Program.
• Section 3 — Testing (pp. 16–24): Mandatory and Random Testing; Reasonable Cause Testing; Follow-Up Testing; Collection Procedures and Testing Protocols; Positive Test Results; Notice to the Parties; Multiple Disciplines for the Same Use; Therapeutic Use Exemption.
• Section 4 — Evaluation and Treatment for Drugs of Abuse (pp. 27–30): Initial Evaluation; Treatment Program; Failure to Comply; Salary Retention provisions.
• Section 5 — Confidential Information (pp. 30–37): Definition; Prohibition of Disclosure; Public Disclosure of Player's Suspension; Disclosure of Information to Clubs; Public Statements Undermining Integrity of the Program (Sec. 5.E); Enforcement; Maintenance of Testing Records.
• Section 6 — Disclosure in Response to Legal Process (pp. 37–39).
• Section 7 — Discipline (pp. 39–50): Performance Enhancing Substance Violations (A — escalating suspensions, currently 80 games first offense, 162 games second, permanent ban third under MLB-MLBPA framework); Stimulant Violations (B); DHEA Violations (C); Failure to Comply with an Initial Evaluation or Treatment Program (D); Conviction for Use or Possession (E); Participation in Sale or Distribution (F); Other Violations (G); Suspensions (H); Restricted List Placement and Reinstatement (I); Completion of Minor League Discipline (J); Multiple Substances (K); Notice to the Player (L); Exclusive Discipline (M).
• Section 8 — Appeals (pp. 51–58): Arbitration Proceedings; Challenges to a Positive Test Result; Procedures for Appeal of a Positive Test Result for a PED or a Second-and-Subsequent Positive Test Result for a Stimulant or DHEA; Appeal of Discipline Issued Pursuant to Sec. 7.G.2; Other Appeals.
• Sections 9–12: Educational Programs and Materials; Costs of the Program; Rights of Third Parties; Term (effective January 1, 2022 through December 31, 2026).
• Sections 13–18: Attachments 1–6 (specific testing protocols, foreign professional procedures, free agent procedures, etc.)

Notable provisions

Major League Baseball's Joint Drug Prevention and Treatment Program ('Program') was established by agreement of the Office of the Commissioner of Baseball and the Major League Baseball Players Association (the 'Commissioner's Office,' the 'Players Association' and, jointly, the 'Parties') to: (i) educate Players on the risks associated with the use of Prohibited Substances (defined in Section 2 below); (ii) deter and end the use of Prohibited Substances by Players; and (iii) provide for, in keeping with the overall purposes of the Program, an orderly, systematic, and cooperative resolution of any disputes that may arise concerning the existence, interpretation, or application of this Program.— JDPTP preamble

The Program covers: (i) all Players on the Major League Clubs' 40-man rosters; (ii) any Player on the Restricted List or the 60-day Injured List; (iii) any Player who becomes a free agent under Article XIX or Article XX of the Basic Agreement; (iv) any Player who is released from a Major League roster unless the Player voluntarily retires or signs a Minor League contract or a contract with a club in an unaffiliated professional baseball league; and (v) Foreign Professionals and Certain Free Agents, as specified in Attachments 3 and 4 to the Program ('Players').— JDPTP preamble

The Parties shall jointly select an individual to serve as the Independent Program Administrator ('IPA'). Such individual shall have no affiliation with the Commissioner's Office, any Major League Club or the Players Association.— JDPTP Sec. 1.A.1(a)

The IPA shall be appointed for a term commencing on January 1, 2022 and ending on December 31, 2026.— JDPTP Sec. 1.A.1(b)

Further context

Joint Drug Prevention and Treatment Program (2022–2026)

The current Major League Baseball drug program, jointly adopted by the Office of the Commissioner of Baseball and the MLBPA, effective January 1, 2022 through December 31, 2026 (coextensive with the 2022–2026 Basic Agreement).

What this document does

The JDPTP is the operative document for every drug-related testing, treatment, and discipline matter in MLB. It defines:

• Who is covered — all 40-man-roster players, Restricted/IL players, free agents, and released players (with carve-outs).
• What is prohibited — PEDs, stimulants, DHEA, drugs of abuse, diuretics/masking agents — with a defined mechanism for adding substances.
• How testing works — mandatory random, reasonable cause, and follow-up testing protocols, with collection by an accredited laboratory under the supervision of an Independent Program Administrator (IPA) jointly selected by the Parties.
• What happens after a positive test — notice procedures, multiple-discipline rules, therapeutic use exemptions, and the full appellate framework via the Grievance Procedure of the Basic Agreement.
• What discipline applies — by substance category, with escalating suspensions and a permanent-ban provision for repeated PED violations.

Structural note: it's joint

The JDPTP's central structural feature — and the union's biggest historical win in the drug-policy space — is that it is jointly adopted and jointly administered. The Independent Program Administrator has no affiliation with either party. Disputes go to grievance arbitration. Discipline can be appealed under Section 8. This is fundamentally different from the pre-2002 era, when drug policy was largely a unilateral commissioner-office matter (see the 1991 Vincent and 1997 Selig drug-policy memos, currently in the WANTLIST).

Key provisions

For any drug-related discipline analysis, this document is the operative source. Notable provisions:

• Section 5.E (Public Statements Undermining Integrity of the Program) — restrictions on player public criticism of the program. Notable speech restriction in a labor context.
• Section 7.A's escalating PED discipline (80/162/permanent) — the current schedule, distinct from the 50/100/permanent regime in the post-Mitchell era.
• Section 7.G (Other Violations) — the catch-all that is invoked when a violation does not fit one of the enumerated categories.
• Independent Program Administrator (IPA) selection (Sec. 1.A) — the structural protection against unilateral commissioner discipline.
• Term (Sec. 12) — the JDPTP expires concurrently with the Basic Agreement (December 31, 2026). The drug program is itself part of the 2026 CBA negotiation.

Related documents in the archive

• 2022-03-10_cba_mlb-cba-2022-2026.md — Basic Agreement; the Grievance Procedure under Article XI of the CBA is the appellate framework for JDPTP disputes.

Verification status

verified. Both the MLBPA-hosted and MLB-hosted copies were downloaded and confirmed bit-identical (same SHA256: 51b13c4f…). This is the strongest possible two-source confirmation — identical files served by both parties to the agreement.

Related documents

Related documents

2022–2026 MLB Basic Agreement

Source provenance

• Primary source
• Wayback Machine archive
• Major League Baseball (img.mlbstatic.com — MLB image/asset server)